ALZpath’s pTau217 antibody was released in 2023 and continues to be a key focus in Alzheimer’s disease research and ...

Researchers say the repurposed drugs could accelerate a long-stalled path toward meaningful Alzheimer’s treatment. (Scripps ...

Although it's not always easy to determine if an individual can make decisions, a judge understands the obvious that a ...

Key Takeaways At AAIC 2025, the Alzheimer's Association released the first in a series of clinical practice guidelines for the diagnosis, treatment and care of Alzheimer's and all other ...

Microglia, a type of brain immune cell, can gobble up amyloid beta protein, which clumps together into toxic aggregates ...

Scientists at UCSF have uncovered how certain immune cells in the brain, called microglia, can effectively digest toxic ...

The Alzheimer's Association® will present 10 scientific awards at the Alzheimer's Association International Conference® 2025 (AAIC®), recognizing researchers for their expertise, noteworthy ...

The opinion will now be referred to the European Commission for final regulatory decision on donanemab  INDIANAPOLIS, July 25 ...

Massive proteomics database links gene variant APOE 4 to chronic inflammation.

Trontinemab's Phase Ib/IIa Brainshuttle AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining Design of the Phase III TR ...

Aggression in Alzheimer’s can’t always be prevented, but it can often be de-escalated when it occurs. Each person is unique. What works for your loved one may not be as effective for someone else.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...